Now available REVTORPYK™

REVTORPYK™ (gedatolisib) is indicated for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer who are PIK3CA mutation-negative, following disease progression on or after at least one prior line of endocrine therapy in the metastatic setting.

Please see full prescribing information here.